<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[Editorial Board of Journal of Pharmaceutical Research -->New Drug Registration and Evaluation Technology]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on the development and evaluation of buccal films]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Buccal films refer to adhesive in the oral cavity, through the mucosal absorption after the systemic action of the film. As one of the representative dosage forms of oral mucosal administration, buccal films have the advantages of rapid onset, avoiding gastrointestinal degradation and first-pass effect of drugs in the liver, and improving patient compliance. Based on the development and approval of buccal films in recent years, the evaluation of buccal films are put forward in terms of formulation, manufacturing process and quality research and control. These discussions are expected to guide the development and evaluation of buccal films, and promote the approval and marketing of high-quality buccal films with clinical needs.]]></description>
<pubDate>2024/10/9 16:27:01</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[WANG Lu, HU Yanchen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Lu, HU Yanchen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409007&flag=1]]></guid><cfi:id>29</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Consideration of pharmaceutical study for the generic drugs of ophthalmic suspension]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ophthalmic suspension is a sterile liquid preparation formed by dispersing insoluble solid drugs in a dispersion medium. This paper preliminarily discusses the formulation, manufacturing process, quality study, container and stability study of ophthalmic suspension, and summarizes the key study parameters of ophthalmic suspension development process from the domestic and foreign references, in order to help the industry to develop ophthalmic suspension generic drugs.]]></description>
<pubDate>2024/10/9 16:27:01</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[WANG Jiaqiang, WEI Tingting, YANG Wenzhi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Jiaqiang, WEI Tingting, YANG Wenzhi</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409008&flag=1]]></guid><cfi:id>28</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[磷酸西格列汀片仿制药药学研究的相关考虑]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/9/11 10:05:16</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[吴小飞，刘丹杏，张歆，王宏亮]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>吴小飞，刘丹杏，张歆，王宏亮</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408009&flag=1]]></guid><cfi:id>27</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[化学药品仿制药眼用制剂质量研究总体要求和关注点探讨]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/9/11 10:05:16</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[张保梅，罗俊永，陆骁骏，李珊珊]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张保梅，罗俊永，陆骁骏，李珊珊</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408010&flag=1]]></guid><cfi:id>26</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Interpretation of “Guidance on Polymorphism Study of Chemical Generic Drugs(Trial)”]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, polymorphism study of chemical drugs has become a research hotspot in the international pharmaceutical field, in order to encourage and promote the development of chemical generic drugs in domestic pharmaceutical enterprises, and clarify the focus of crystal research in the process of chemical generic drug research and development, the Center for Drug Evaluation of National Medical Products Administration officially issued the " Guideline on  Polymorphism Study of Chemical Generic Drugs" on January 4, 2022. A detailed interpretation of the guidance is provided in this paper，combined with the drafting process of the guidance and fully considering the characteristics of generic drug development，in order to help applicants to get a better understanding and application.]]></description>
<pubDate>2024/7/22 17:21:22</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[YANG Liu, HE Yan, HU Yuxi, XU Zhenyu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Liu, HE Yan, HU Yuxi, XU Zhenyu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406008&flag=1]]></guid><cfi:id>25</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Some considerations on the study of Multivitamins and minerals preparation for oral administration]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Multivitamins and minerals preparation for oral administration contains a variety of vitamins and minerals. Considering the complexity of the prescription, further exploration methods of quality research are needed. Based on the preparation characteristics, review experience and guidances released in many countries, this paper expounds some considerations on the study of multivitamins and minerals preparation, in order to provide some references for future research．]]></description>
<pubDate>2024/7/22 17:21:22</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[LIU Danxing, WU Xiaofei, WANG Huan, WANG Hongliang, BAI Yu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Danxing, WU Xiaofei, WANG Huan, WANG Hongliang, BAI Yu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406009&flag=1]]></guid><cfi:id>24</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Consideration of bioequivalence test waiver of Levofloxacin Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Generic drug application and consistency evaluation of levofloxacin tablets are popular in recent years. This article discusses the policies and guiding principle of bioequivalence test waiver，and summarizes the technical requirements of bioequivalence test waiver for different specifications of Levofloxacin Tablets，in order to provide better research and application route for research unit.]]></description>
<pubDate>2025/1/9 14:34:36</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[ZHAO Lei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Lei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412010&flag=1]]></guid><cfi:id>23</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[General considerations for generic pharmaceutical research of tenofovir alafenamide fumarate]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, the application of generic nucleoside (acid) anti hepatitis B drugs represented by tenofovir alafenamide fumarate (TAF) has received widespread attention. This article summarizes and organizes the physical and chemical properties, synthesis routes, quality studies, and process characteristics of propofol tenofovir fumarate. Combined with relevant literature patents and review experience, suggestions for pharmaceutical research on propofol tenofovir fumarate (TAF) are comprehensively proposed, aiming to provide some reference for subsequent research and development.]]></description>
<pubDate>2025/1/9 14:34:36</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[ZHANG Xin, WU Xiaofei, WANG Hongliang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xin, WU Xiaofei, WANG Hongliang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412011&flag=1]]></guid><cfi:id>22</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on pharmaceutical research of overfilling for generic injections]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202411010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Overfilling of generic injections was a key issue that needs to be focused in the process of drug development, manufacturing and registration review. This article summarized the regulatory requirements of domestic and foreign drug regulatory agencies for overfill, and analyzed the concerns, typical cases and common problems of overfill research from the perspective of review, aiming to provide references for the development, manufacturing and the registration of injection generic drugs of overfill.]]></description>
<pubDate>2024/12/5 16:48:42</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[DONG Chenhuan, JIANG Xifeng, GONG Qing, ZHANG Xinfang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DONG Chenhuan, JIANG Xifeng, GONG Qing, ZHANG Xinfang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202411010&flag=1]]></guid><cfi:id>21</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Introduction of common deficiencies and issues in CMC review of generic drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Regulatory agencies in various countries have issued a series of documents on common deficiencies and issues to improve the efficiency of generic drug review, which play an important role in standardizing and improving the quality of filing information. This paper intends to summarize the guidelines or technical documents that have been issued by FDA, EMA and NMPA related to the improvement of the quality of the declaration information, and introduce the common issues related to the pharmacy technical review of the generic drug declarations therein, in the hope that it can provide a glimpse of the high-quality development and reform of China's generic drugs.]]></description>
<pubDate>2024/11/18 11:12:32</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[ZHANG Junlin, WANG Shaorong, WANG Shuhua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Junlin, WANG Shaorong, WANG Shuhua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410008&flag=1]]></guid><cfi:id>20</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Considerations of common problems on the development of chewable tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This review lists the technical requirements of chewable tablets issued by some domestic and foreign regulatory agencies, and analyzes the common problems in chewable tablets registration and application materials combined with the actual drug evaluation. This paper aims to propose the key issues that should be considered in the development of chewable tablets, so as to avoid or reduce the occurrence of adverse events in clinical use, improve the acceptability of patients, and ensure the safety, effectiveness and quality control of drugs.]]></description>
<pubDate>2024/11/18 11:12:32</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[ZHANG Xin, WU Xiaofei, LIU Danxing, WANG Hongliang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xin, WU Xiaofei, LIU Danxing, WANG Hongliang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410009&flag=1]]></guid><cfi:id>19</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of formulation similarity requirements for biowaiver of bioequivalence studies in multi-strength fixed-dose combinations by the European Medicines Agency]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This article systematically analyzes the European Medicines Agency (EMA)'s requirements for formulation similarity when applying for bioequivalence (BE) waivers for other specifications of multi-specification chemical compound pharmaceutical preparations, based on specifications that have already passed BE trials. The analysis is conducted in accordance with Investigation of bioequivalence - Scientific guideline (Rev.1, 2010) and Clinical pharmacology and pharmacokinetics: questions and answers (Sections 6.4 and 6.5, 2020—2021) issued by EMA. The findings aim to provide scientific references for the development and registration of FDCs in domestic markets.]]></description>
<pubDate>2025/10/14 16:33:20</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[CHEN Si, MI Xianwei, SHI Jing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Si, MI Xianwei, SHI Jing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509008&flag=1]]></guid><cfi:id>18</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pharmaceutical research on topical ointments and creams preparations for cutaneous application]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ointments and creams are semi-solid dosage forms designed for therapeutic efficacy through topical cutaneous application. Based on the current status of global development and regulatory submissions for these dosage forms, this article systematically explores their pharmaceutical research aspects, including formulation development, manufacturing processes and quality control strategies. Focusing on critical aspects such as excipient matrix selection, process parameter refinement, and their impacts on product performance, we present preliminary perspectives to highlight key challenges in developing these formulations. Although the perspectives presented may not be exhaustive, this exploration aims to provide actionable references and insights to advance research and development in this field.]]></description>
<pubDate>2025/10/14 16:33:20</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[LI Yanjie, LIU Yan, LIU Mengsi, JIANG Dianzhuo]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Yanjie, LIU Yan, LIU Mengsi, JIANG Dianzhuo</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509009&flag=1]]></guid><cfi:id>17</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Review on research progress and marketing application of percutaneous drug delivery systems]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In this paper, different types of transdermal drug delivery systems at the present stage are reviewed, their prescribing process characteristics, mechanism of action, and research and development status are described and summarized. The marketing situation of transdermal patch in China, the United States, Europe and Japan is reviewed, typical products of micronedle TDDs and iontophors TDDs are listed, and other new penetration promoting technologies are introduced. The development prospect and challenges of TDDs are discussed.]]></description>
<pubDate>2025/7/16 8:54:05</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[GONG Chenchen, LIU Yan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GONG Chenchen, LIU Yan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506009&flag=1]]></guid><cfi:id>16</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Interpretation of “Guideline for Pharmaceutical Research of Chemical Generic Drug Oral Solutions”]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Oral solutions have the characteristics of uniform dose distribution, flexible dosage administration, and good patient compliance, and has been paid more attention in the field of domestic drug development in recent years. In order to promote the development of domestic generic drugs and clarify the pharmaceutical technical requirements in the research and development process of chemical generic drug oral solutions, the Center for Drug Evaluation of National Medical Products Administration officially issued the "Guideline for Pharmaceutical Research of Chemical Generic Drug Oral Solutions" on July 8, 2024. This article provides a detailed interpretation, combined the drafting process of the guideline, in order to facilitate better understanding and application by related researchers.]]></description>
<pubDate>2025/7/16 8:54:05</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[WANG Gongfu<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Gongfu<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506010&flag=1]]></guid><cfi:id>15</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Basic considerations for pharmaceutical research and evaluation of generic low-molecular-weight heparins]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In February 2024，CDE of NMPA issued the <i>Guideline of pharmaceutical research and evaluation of generic low-molecular-weight heparins</i> (<i>Trial</i>). This article combines the drafting background of the guideline, the main characteristics of generic low-molecular-weight heparins, and focuses on analyzing and discussing the difficulties and concerns in pharmaceutical research and evaluation of this type of generic drugs. The technical requirements for pharmaceutical research and evaluation are clarified. The purpose is to establish a comprehensive and systematic in vitro pharmaceutical research and evaluation system, providing more technical support for the consistency evaluation of such complex products and promoting their high-quality development.]]></description>
<pubDate>2025/5/9 9:16:54</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[ZHAO Na, SHI Jing, XU Zhenyu, MI Xianwei, CHEN Si, CAO Qili]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Na, SHI Jing, XU Zhenyu, MI Xianwei, CHEN Si, CAO Qili</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504008&flag=1]]></guid><cfi:id>14</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on pharmaceutical research concerns of chemical orally disintegrating tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Orally disintegrating tablets are tablets that can disintegrate or dissolve quickly without water in the mouth. As one of the dosage forms of tablets, orally disintegrating tablets have the advantages of easy to take, rapid disintegration or dissolution in the mouth, which is helpful to improve the patients compliance. Discussions on formulation and manufacturing process, quality research and quality control, stability and packaging of orally disintegrating tablets were based on the marketing drug, pharmacopoeia standards and guiding principles at home and abroad. These discussions are expected to guide the development of orally disintegrating tablets, and promote marketing of high-quality orally disintegrating tablets to meet the needs of specific patients.]]></description>
<pubDate>2025/5/9 9:16:55</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[ZHANG Zhaorui, HU Yanchen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Zhaorui, HU Yanchen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504009&flag=1]]></guid><cfi:id>13</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Overview and reflections on the drug registration management systems of China, the United States, Japan and European Union]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To provide international references for optimizing and improving the drug registration management system of China. <b>Methods</b>  The drug registration management systems of China,the United States,Japan and the European Union,were summarized and analyzed systematically, including the regulatory authorities,law and regulations and registration procedures. <b>Results</b>  The drug registration management system of China should be implemented in terms of law and regulations、review and approved process and efficiency, inernational coordination. <b>Conclusion</b>  Global drug regulation is showing a trend of scientific, international and efficient development. It is suggested that China should build a more efficient and authoritative drug registration management by drawing on the international management experience.which can provide institutional support for safeguarding public health rights and high-quality development of the pharmaceutical industry.]]></description>
<pubDate>2026/1/6 16:37:08</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[DING Xiaoli, LI Mengjiao, TAN Liyuan, YAO Shangchen, CHEN Hua, SUN Huimin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DING Xiaoli, LI Mengjiao, TAN Liyuan, YAO Shangchen, CHEN Hua, SUN Huimin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512007&flag=1]]></guid><cfi:id>12</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The key points and common problem analysis for pharmaceuticalresearch and development of biological products]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Under the new regulatory framework for drug registration, the verification of pharmaceutical research and development of biological products as a crucial supervisory tool to promote the authenticity and traceability of data in the drug development process, as well as to advance the standardization and high-quality development of the pharmaceutical R&D. Based on the characteristics of biological products and practical inspection experiences in recent years. This article summarizes and analyzes the key focus points and common issues identified during the site inspections of biological products. The aim is to provide insights for the research and development, and registration of biological products, as well as to offer references for the related inspections.]]></description>
<pubDate>2026/1/6 16:37:08</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[ZHANG Pin<sup>1</sup>, SONG Kai<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Pin<sup>1</sup>, SONG Kai<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512008&flag=1]]></guid><cfi:id>11</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Recent advances in rheological evaluation methods for generic semi-solid preparations]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Rheology plays a pivotal guiding role in the development of semi-solid preparations and serves as a core indicator for their quality evaluation and stability assessment. This article systematically reviews recent advances in rheological evaluation methodologies. It focuses on comparing the regulatory requirements for rheological characterization of generic semi-solid preparations set forth by FDA, EMA and NMPA, highlighting the stringent statistical standards of EMA and their recent updates. The article discusses current methods for evaluating rheological equivalence, aiming to provide methodological references and practical guidance for researchers and regulatory submission units.]]></description>
<pubDate>2025/12/9 13:53:33</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[LI Yanjie, JIANG Dianzhuo, LIU Mengsi, ZHANG Zhongheng, LIU Yan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Yanjie, JIANG Dianzhuo, LIU Mengsi, ZHANG Zhongheng, LIU Yan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511007&flag=1]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[General considerations for the pharmaceutical research of generic drugs of Perampanel Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Perampanel Tablets are the first highly selective noncompetitive AMPA receptor antagonist approved by the FDA, with clear efficacy and good tolerability in the treatment of epilepsy. In recent years, it has gradually become a first-line clinical drug, and its domestic generic drug application has become a hot topic. This article summarized the approved market situation at home and abroad through research  on relevant literature, and discusses the main focus of pharmaceutical research and requirement for additional strength biowaiver on this variety, aiming to provide some reference for product development.]]></description>
<pubDate>2025/12/9 13:53:33</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[WANG Gongfu, LI Chen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Gongfu, LI Chen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511008&flag=1]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[皮肤外用半固体化学仿制药药学研究现状与思考]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/9/15 9:10:51</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[李珊珊，孙影，申丽先，谢琰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李珊珊，孙影，申丽先，谢琰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608007&flag=1]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[舌下片研究进展及药学研究探讨]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/9/15 9:10:51</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[沈波，潘静]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>沈波，潘静</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608008&flag=1]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Challenges and optimized paths of China's innovative drug review mechanism]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Currently, China is in a critical period of transitioning from a major pharmaceutical country to a powerful pharmaceutical nation.The reform of the innovative drug evaluation mechanism has achieved remarkable results, with continuous improvement in regulations and policies, refinement of evaluation standards, and significant enhancement in evaluation efficiency. However, there are still challenges such as insufficient operability of some regulations, lagging evaluation standards in frontier fields, and inadequate implementation of intelligent evaluation. This article delves into the current predicaments and proposes optimization paths from refining regulatory content, improving standards in frontier fields, strengthening team building, and deepening the integration of big data, artificial intelligence, and evaluation business. It aims to provide some theoretical references for the optimization of the innovative drug evaluation mechanism.]]></description>
<pubDate>2026/6/15 15:35:39</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[ZHANG Yu, MA Shaoqing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yu, MA Shaoqing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605008&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on pharmaceutical research concerns of chemical generic drugs cataplasms]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cataplasm is made by mixing drug substances with a suitable hydrophilic matrix and then coating it on the backing material. Cataplasm has the advantages of convenient use, accurate dosage, avoidance of the first-pass effect of the liver and little skin irritation.Discussions on formulation and manufacturing process, quality research and quality control, stability and packaging of cataplasm were based on the marketing drug and pharmacopoeia standards. These discussions are expected to guide the development of cataplasm, and promote marketing of high-quality cataplasms.]]></description>
<pubDate>2026/6/15 15:35:39</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[ZHANG Zhaoru, FENG Xue, HU Yanchen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Zhaoru, FENG Xue, HU Yanchen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605009&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[General considerations for the prescription and process development
of chemical generic compound bilayer tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Compound bilayer tablets have been widely concerned in the development of novel solid formulations because of its advantages including enhancing drug efficacy, reducing side effects and improving patient compliance by combining medications or adjusting the rate of drug release. This review summarizes the key points in prescription screening and process development of chemical generic compound bilayer tablets, combining the literature patents, relevant domestic and foreign drug laws and regulations. This includes the characteristics of active pharmaceutical ingredients, the selection of excipients, the design of multi-strengths prescription, the development of bi-layer process and batch amplification, etc., in order to provide a reference for generic compound bilayer tablets drug development.]]></description>
<pubDate>2026/3/17 14:12:45</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[LYU Yaping, ZHAO Na, SUN Yuanpeng, XIE Yan, ZHANG Junlin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LYU Yaping, ZHAO Na, SUN Yuanpeng, XIE Yan, ZHANG Junlin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602010&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on the research of supplemental applications for post-approval oral modified-release formulations]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The post-approval CMC（chemical, manufacturing and control）changes are important parts of pharmaceutical product lifecycle. The changes considered to have a substantial potential to have a significant effect on safety, efficacy and quality of modified-release formulations. The pharmaceutical sponsors who intend to change the batch size，specification，storage condition and strength of some oral modified-release formulations should submit supplemental applications for major changes. Based on specific cases of oral modified-release formulations, the pharmaceutical considerations were put forward to assess the effects of the change and change research, in order to provide references for conduct change research and management.]]></description>
<pubDate>2026/3/17 14:12:45</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[SI Xiaofei, WANG Shuhua, LI Yanjie, JIANG Dianzhuo]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SI Xiaofei, WANG Shuhua, LI Yanjie, JIANG Dianzhuo</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602011&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[美欧日罕见病用药市场独占期研究及相关借鉴思路]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/11/17 13:22:24</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[陈新，袁利佳，王骏]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈新，袁利佳，王骏</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610007&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[滴眼剂包装材料相容性和包装系统密封性研究的相关考虑]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/11/17 13:22:25</pubDate>
<category><![CDATA[New Drug Registration and Evaluation Technology]]></category>
<author><![CDATA[李珊珊，罗俊永，崔文静，孙影]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李珊珊，罗俊永，崔文静，孙影</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610008&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>